Cargando…

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis

OBJECTIVE: Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naïve patients with spondyloarthritis (SpA) are lacking. The objectives were to compare treatment retention in biologics-naïve patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindström, Ulf, Glintborg, Bente, Di Giuseppe, Daniela, Nordström, Dan, Aarrestad Provan, Sella, Gudbjornsson, Bjorn, Askling, Johan, Lund Hetland, Merete, Aaltonen, Kalle, Krogh, Niels Steen, Geirsson, Arni Jon, Jacobsson, Lennart T H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827791/ https://www.ncbi.nlm.nih.gov/pubmed/31749988 http://dx.doi.org/10.1136/rmdopen-2019-001079

Ejemplares similares

Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
por: Chatzidionysiou, Katerina, et al.
Publicado: (2018)

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
por: Delcoigne, Benedicte, et al.
Publicado: (2022)

Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries
por: Glintborg, Bente, et al.
Publicado: (2022)

Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry
por: Gudbjornsson, Bjorn, et al.
Publicado: (2018)

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
por: Cordtz, Rene Lindholm, et al.
Publicado: (2022)

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
por: Delcoigne, Benedicte, et al.
Publicado: (2023)

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2019)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Retention rates of adalimumab, etanercept, and infliximab as first‐ or second‐line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)
por: Soubrier, Martin, et al.
Publicado: (2018)

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study
por: Moorkens, Evelien, et al.
Publicado: (2020)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
por: Li, Kun-Peng, et al.
Publicado: (2018)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Physicochemical Characterization of Altebrel™, a Proposed Etanercept Biosimilar
por: Fazel, Ramin, et al.
Publicado: (2019)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Acute Q Fever in an Ankylosing Spondyloarthritis Patient Treated with Etanercept
por: Guiga, A., et al.
Publicado: (2021)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis
por: Provan, Sella A, et al.
Publicado: (2021)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Infliximab and Etanercept Are Equally Effective in Reducing Enterocyte APOPTOSIS in Experimental Colitis
por: Fries, Walter, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7o39abn64oip12n62g9ofomc5a